Close Menu

Scripps Genomic Medicine

The R&D deal targets oncology and cardiovascular disease.

The study, which surveyed more than 2,000 people, found that the "results of a direct-to-consumer genomic risk test do not affect health-related behavior."

A survey primarily using Scripps employees and Navigenics test offering shows that 50 percent of DTC genomics test takers have concerns, but over 80 percent want to know risks even of non-preventable diseases.

"We are concentrating on two initial areas — diabetes and aging research," Eric Topol, chief academic officer of Scripps Health, said. "Diabetes PGx work is of vital interest to Scripps, Sanofi, and the public."

Under terms of the alliance, a Sanofi-aventis Group subsidiary will fund each year up to three Discovery Innovation Grants intended to offer flexible financing for innovative research proposals from investigators at a division of Scripps Health.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.